CARsgen Therapeutics Holdings Limited
HKSE: 2171.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zonghai Li
- Employees
- 465
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- HK$12.7B
- Website
- https://www.carsgen.com
Loading 2171…
Loading profile data…Frequently asked questions about 2171
What does CARsgen Therapeutics Holdings Limited (2171.HK) do?
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product ca...
Where does 2171.HK trade?
CARsgen Therapeutics Holdings Limited (2171.HK) trades on the Hong Kong Stock Exchange.
What sector is 2171.HK in?
CARsgen Therapeutics Holdings Limited (2171.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CARsgen Therapeutics Holdings Limited?
Zonghai Li is the chief executive officer of CARsgen Therapeutics Holdings Limited (2171.HK).
Where is CARsgen Therapeutics Holdings Limited headquartered?
CARsgen Therapeutics Holdings Limited is headquartered in China.
Does 2171.HK pay a dividend?
CARsgen Therapeutics Holdings Limited (2171.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2171.HK go public?
CARsgen Therapeutics Holdings Limited (2171.HK) completed its initial public offering in 2021.